EDIT (Editas Medicine) NonCurrent Deferred Liabilities: $91.69 Mil (As of Mar. 2026)


EDIT Editas Medicine Inc EDIT
45 GF Score
Price $3.65
GF Value $1.85
Valuation Significantly Overvalued
! 11 Warning Signs
View Full Analysis

What is Editas Medicine NonCurrent Deferred Liabilities?

Editas Medicine EDIT -2.13% 45 NonCurrent Deferred Liabilities is $91.69 Mil as of Mar. 2026. GuruFocus rates EDIT with a GF Score™ of 45/100 and a GF Value™ of $1.85 (Significantly Overvalued). The stock has 11 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Editas Medicine's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $91.69 Mil.

Editas Medicine NonCurrent Deferred Liabilities Related Terms

Editas Medicine NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Editas Medicine's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Editas Medicine NonCurrent Deferred Liabilities Chart

Editas Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.89 60.67 60.67 106.64 98.11

Editas Medicine Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.78 105.87 108.27 98.11 91.69
EDIT
45GF Score
Editas Medicine Inc EDIT
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $91.69 Mil mean?
Editas Medicine (EDIT) has a NonCurrent Deferred Liabilities of $91.69 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Editas Medicine and its competitors.
Is Editas Medicine's NonCurrent Deferred Liabilities too high?
Editas Medicine's current NonCurrent Deferred Liabilities is $91.69 Mil. Overall, Editas Medicine has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's NonCurrent Deferred Liabilities compare to SGMT and AUTL?
Editas Medicine's NonCurrent Deferred Liabilities of $91.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Editas Medicine and its competitors. Editas Medicine's current NonCurrent Deferred Liabilities is $91.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.85, compared to a current price of $3.65 — trading 97.3% above its estimated fair value. The current NonCurrent Deferred Liabilities is $91.69 Mil. Editas Medicine's overall GF Score™ is 45/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Editas Medicine (EDIT), the current NonCurrent Deferred Liabilities is $91.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $3.65 is trading 97.3% above its estimated GF Value™ of $1.85. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

  • NonCurrent Deferred Liabilities: $91.69 Mil
  • GF Value™: $1.85 vs. price of $3.65 (97.3% above fair value)
  • GF Score™: 45/100 with 11 warning signs

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges 0IFK:UK8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
45GF Score

Get the complete analysis for EDIT

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.65
Price
$1.85
GF Value